Lisdexamfetamine Dimesylate (LDX)

DRUG4 trials

Sponsors

Shire

Conditions

ADHDAttention-Deficit Hyperactivity Disorder

Phase 1

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

CompletedNCT01010750

ShireAttention-Deficit Hyperactivity Disorder

Start: 2010-01-05End: 2010-03-28Updated: 2021-06-14

Phase 3

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

CompletedNCT00763971

Start: 2008-11-17End: 2011-03-16Updated: 2021-06-14

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

CompletedNCT00764868

Start: 2008-11-13End: 2010-04-22Updated: 2021-06-14

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

CompletedNCT00784654

Start: 2009-01-27End: 2011-10-26Updated: 2021-06-09

Related Papers

Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

2018-05-0114 citations

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.

2017-07-0128 citations

Maintenance of Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Randomized-Withdrawal Study Design

Journal of the American Academy of Child & Adolescent Psychiatry2014-03-0455 citations

A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

2013-02-0132 citations